A research in Germany showed that homozygous carriers of IBD risk-increasing IL23R variants were more apt to respond to anti-TNF than homozygous carriers of IBD risk-decreasing IL23R variants (63). This evidence concerns the gene TNF and inflammatory bowel disease.